Anja Mehnert1, Elmar Brähler2, Hermann Faller2, Martin Härter2, Monika Keller2, Holger Schulz2, Karl Wegscheider2, Joachim Weis2, Anna Boehncke2, Bianca Hund2, Katrin Reuter2, Matthias Richard2, Susanne Sehner2, Sabine Sommerfeldt2, Carina Szalai2, Hans-Ulrich Wittchen2, Uwe Koch2. 1. Anja Mehnert, Elmar Brähler, Carina Szalai, University Medical Center Leipzig, Leipzig; Anja Mehnert, Martin Härter, Holger Schulz, Karl Wegscheider, Susanne Sehner, Uwe Koch, University Medical Center Hamburg-Eppendorf, Hamburg; Hermann Faller, Matthias Richard, University of Würzburg, Würzburg; Monika Keller, Sabine Sommerfeldt, University Hospital Heidelberg, Heidelberg; Joachim Weis, Anna Boehncke, Tumor Biology Center, University of Freiburg; Bianca Hund, Rhein-Jura-Klinik, Bad Säckingen; Bianca Hund, Katrin Reuter, University Medical Center Freiburg, Freiburg; Carina Szalai, Psychosocial Counseling Center for Cancer Patients, Zwickau; Hans-Ulrich Wittchen, Institute of Clinical Psychology and Psychotherapy and Center of Clinical Epidemiology and Longitudinal Studies, Technical University Dresden, Dresden; Elmar Brähler, Universal Medical Center Mainz, Mainz, Germany. anja.mehnert@medizin.uni-leipzig.de. 2. Anja Mehnert, Elmar Brähler, Carina Szalai, University Medical Center Leipzig, Leipzig; Anja Mehnert, Martin Härter, Holger Schulz, Karl Wegscheider, Susanne Sehner, Uwe Koch, University Medical Center Hamburg-Eppendorf, Hamburg; Hermann Faller, Matthias Richard, University of Würzburg, Würzburg; Monika Keller, Sabine Sommerfeldt, University Hospital Heidelberg, Heidelberg; Joachim Weis, Anna Boehncke, Tumor Biology Center, University of Freiburg; Bianca Hund, Rhein-Jura-Klinik, Bad Säckingen; Bianca Hund, Katrin Reuter, University Medical Center Freiburg, Freiburg; Carina Szalai, Psychosocial Counseling Center for Cancer Patients, Zwickau; Hans-Ulrich Wittchen, Institute of Clinical Psychology and Psychotherapy and Center of Clinical Epidemiology and Longitudinal Studies, Technical University Dresden, Dresden; Elmar Brähler, Universal Medical Center Mainz, Mainz, Germany.
Abstract
PURPOSE: To provide the 4-week prevalence estimates of mental disorders in cancer populations. PATIENTS AND METHODS: We enrolled adult patients with cancer from in- and outpatient care facilities, using a proportional stratified random sample based on the nationwide cancer incidence in Germany. Patients who scored 9 or above on the Patient Health Questionnaire (PHQ-9) were administered to the standardized computer-assisted Composite International Diagnostic Interview for mental disorders adapted for cancer patients (CIDI-O). A random sample of those with a PHQ-9 score that was less than 9 were selected for a CIDI-O. RESULTS: A total of 5,889 patients were identified, which led to 4,020 participants (a 68.3% response rate); of those, 2,141 patients were interviewed. The 4-week total prevalence for any mental disorder was 31.8% (95% CI, 29.8% to 33.8%); this included any anxiety disorder (11.5%; 95% CI, 10.2% to 12.9%), any adjustment disorder (11.1%; 95% CI, 9.7% to 12.4%), any mood disorder (6.5%; 95% CI, 5.5% to 7.5%), any somatoform/conversion disorder (5.3%; 95% CI, 4.3% to 6.2%), nicotine dependence (4.5%; 95% CI, 3.6% to 5.4%), alcohol abuse/dependence (0.3%; 95% CI, 0.1% to 0.6%), any mental disorder resulting from general medical condition (2.3%; 95% CI, 1.7% to 2.9%), and any eating disorder (0%). The highest prevalence for any mental disorder was found in patients with breast cancer (41.6%; 95% CI, 36.8% to 46.4%), followed by patients with head and neck cancer (40.8%; 95% CI, 28.5% to 53.0%). The lowest prevalence was found in patients with pancreatic cancer (20.3%; 95% CI, 8.9% to 31.6%) and stomach/esophagus cancers (21.2%; 95% CI, 12.8% to 29.6%). CONCLUSION: Our findings provide evidence for the strong need for psycho-oncological interventions.
RCT Entities:
PURPOSE: To provide the 4-week prevalence estimates of mental disorders in cancer populations. PATIENTS AND METHODS: We enrolled adult patients with cancer from in- and outpatient care facilities, using a proportional stratified random sample based on the nationwide cancer incidence in Germany. Patients who scored 9 or above on the Patient Health Questionnaire (PHQ-9) were administered to the standardized computer-assisted Composite International Diagnostic Interview for mental disorders adapted for cancerpatients (CIDI-O). A random sample of those with a PHQ-9 score that was less than 9 were selected for a CIDI-O. RESULTS: A total of 5,889 patients were identified, which led to 4,020 participants (a 68.3% response rate); of those, 2,141 patients were interviewed. The 4-week total prevalence for any mental disorder was 31.8% (95% CI, 29.8% to 33.8%); this included any anxiety disorder (11.5%; 95% CI, 10.2% to 12.9%), any adjustment disorder (11.1%; 95% CI, 9.7% to 12.4%), any mood disorder (6.5%; 95% CI, 5.5% to 7.5%), any somatoform/conversion disorder (5.3%; 95% CI, 4.3% to 6.2%), nicotine dependence (4.5%; 95% CI, 3.6% to 5.4%), alcohol abuse/dependence (0.3%; 95% CI, 0.1% to 0.6%), any mental disorder resulting from general medical condition (2.3%; 95% CI, 1.7% to 2.9%), and any eating disorder (0%). The highest prevalence for any mental disorder was found in patients with breast cancer (41.6%; 95% CI, 36.8% to 46.4%), followed by patients with head and neck cancer (40.8%; 95% CI, 28.5% to 53.0%). The lowest prevalence was found in patients with pancreatic cancer (20.3%; 95% CI, 8.9% to 31.6%) and stomach/esophagus cancers (21.2%; 95% CI, 12.8% to 29.6%). CONCLUSION: Our findings provide evidence for the strong need for psycho-oncological interventions.
Authors: Andreas Hinz; Joachim Weis; Hermann Faller; Elmar Brähler; Martin Härter; Monika Keller; Holger Schulz; Karl Wegscheider; Uwe Koch; Kristina Geue; Heide Götze; Anja Mehnert Journal: Support Care Cancer Date: 2018-04-26 Impact factor: 3.603
Authors: M Härter; A Jansen; M Berger; H Baumeister; T Bschor; T Harfst; M Hautzinger; L Kriston; C Kühner; H Schauenburg; S G Schorr; F Schneider; R Meister Journal: Nervenarzt Date: 2018-03 Impact factor: 1.214